← Leaderboards
Melvin Reichman
Lankenau Institute For Medical Research
$1,342,323
Attributed
$2,528,746
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $599.4K · FY2007–24$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,528,746 · 4
By mechanism
R01$1,655,480 · 1
R21$615,687 · 2
R43$257,579 · 1
Top collaborators
- George C Prendergast3 shared
- David R Borchelt2 shared
- Alice Marcy1 shared
Most similar at Lankenau Institute For Medical Research
Same institution · by research overlap
- George C Prendergast$9,759,368
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsInnovationCellsComplications Of Diabetes MellitusDiabetes MellitusPhosphotransferasesEnzymesToxic EffectPreclinical Drug DevelopmentPreventPathway InteractionsLeadAdvanced Glycosylation End ProductsProteinsMonitorKidneyKidney DiseasesGlycationHyperglycemiaMethodologyKidney FailurePathogenicityAntagonistComplex
Grant awards (7)
Probing an Unexplored Intracellular Pathway in Diabetes Pathogenesis$515,870
R01 · FY2024 · DK
Probing an Unexplored Intracellular Pathway in Diabetes Pathogenesis$540,254
R01 · FY2023 · DK
Probing an Unexplored Intracellular Pathway in Diabetes Pathogenesis$599,356
R01 · FY2022 · DK
New Drug Discovery Paradigms for Synucleinopathies$201,111
R21 · FY2018 · AG · contact PI
New Drug Discovery Paradigms for Synucleinopathies$258,676
R21 · FY2017 · AG · contact PI
Discovery of FN3K Inhibitors to Treat Diabetic Complications$257,579
R43 · FY2010 · DK
Fructosamine-3-Kinase Assay Development and Validation for HTS$155,900
R21 · FY2007 · NS · contact PI